BR112015017069A2 - process for preparing extract from ceriporialacerata culture medium and pharmaceutical compositions prepared for the prevention or treatment of diabetic diseases and diabetic complications, which contain ceriporialacerata culture medium extract as active ingredient - Google Patents

process for preparing extract from ceriporialacerata culture medium and pharmaceutical compositions prepared for the prevention or treatment of diabetic diseases and diabetic complications, which contain ceriporialacerata culture medium extract as active ingredient

Info

Publication number
BR112015017069A2
BR112015017069A2 BR112015017069A BR112015017069A BR112015017069A2 BR 112015017069 A2 BR112015017069 A2 BR 112015017069A2 BR 112015017069 A BR112015017069 A BR 112015017069A BR 112015017069 A BR112015017069 A BR 112015017069A BR 112015017069 A2 BR112015017069 A2 BR 112015017069A2
Authority
BR
Brazil
Prior art keywords
ceriporialacerata
culture medium
extract
diabetic
prevention
Prior art date
Application number
BR112015017069A
Other languages
Portuguese (pt)
Inventor
Cheon Kim Byoung
Original Assignee
Fugenbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fugenbio Co Ltd filed Critical Fugenbio Co Ltd
Publication of BR112015017069A2 publication Critical patent/BR112015017069A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Abstract

resumo “processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo” a presente invenção refere-se a um processo para preparação de um extrato a partir de meio de cultura de micélio de ceriporialacerata e uma composição farma-cêutica para prevenção ou tratamento de doenças diabéticas e complicações diabé-ticas, preparado através do processo de preparação. de acordo com o processo para preparação de um extrato a partir do meio de cultura de micélio de ceriporialacerata, o extrato contém um teor relativamente alto de exopolissacarídeos em comparação com o processo de preparação convencional de acordo com um documento anterior por estes inventores e assim será capaz de ser usado como um ingrediente para uma composição farmacêutica para doenças diabéticas ou um alimento funcional relevante.Abstract "Process for preparing extract from ceriporialacerata culture medium and pharmaceutical compositions prepared for the prevention or treatment of diabetic diseases and diabetic complications, which contain ceriporialacerata culture medium extract as active ingredient" The present invention relates to to a process for preparing an extract from ceriporialacerata mycelium culture medium and a pharmaceutical composition for the prevention or treatment of diabetic diseases and diabetic complications prepared by the preparation process. According to the process for preparing an extract from the ceriporialacerata mycelium culture medium, the extract contains a relatively high content of exopolysaccharides as compared to the conventional preparation process according to an earlier document by these inventors and so on. capable of being used as an ingredient for a diabetic disease pharmaceutical composition or a relevant functional food.

BR112015017069A 2013-01-18 2013-01-18 process for preparing extract from ceriporialacerata culture medium and pharmaceutical compositions prepared for the prevention or treatment of diabetic diseases and diabetic complications, which contain ceriporialacerata culture medium extract as active ingredient BR112015017069A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2013/000398 WO2014112666A1 (en) 2013-01-18 2013-01-18 Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient

Publications (1)

Publication Number Publication Date
BR112015017069A2 true BR112015017069A2 (en) 2017-07-11

Family

ID=51209750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017069A BR112015017069A2 (en) 2013-01-18 2013-01-18 process for preparing extract from ceriporialacerata culture medium and pharmaceutical compositions prepared for the prevention or treatment of diabetic diseases and diabetic complications, which contain ceriporialacerata culture medium extract as active ingredient

Country Status (9)

Country Link
JP (1) JP2016506719A (en)
KR (1) KR20150103690A (en)
CN (1) CN105142655B (en)
AU (1) AU2013374516B2 (en)
BR (1) BR112015017069A2 (en)
CA (1) CA2897955C (en)
DE (1) DE112013006456T5 (en)
GB (1) GB2529557A (en)
WO (1) WO2014112666A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101682096B1 (en) * 2014-11-03 2016-12-02 (주)퓨젠바이오농업회사법인 Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101645652B1 (en) * 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101682093B1 (en) * 2014-11-03 2016-12-02 (주)퓨젠바이오농업회사법인 Blood pressure reducing composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101737627B1 (en) 2014-11-27 2017-05-19 (주)퓨젠바이오 Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
CN107182201B (en) * 2015-01-30 2021-06-08 福健生物制药有限公司 Pharmaceutical composition for preventing or treating cancer comprising exopolysaccharide produced by Ceriporia lacerata as active ingredient
KR101712590B1 (en) * 2015-08-06 2017-03-07 (주)퓨젠바이오농업회사법인 Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101682108B1 (en) * 2015-10-08 2016-12-02 (주)퓨젠바이오농업회사법인 Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101655882B1 (en) * 2015-10-08 2016-09-08 (주)퓨젠바이오농업회사법인 Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101655878B1 (en) * 2015-10-08 2016-09-08 (주)퓨젠바이오농업회사법인 Composition for preventing hair loss and enhancing hair growth comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101682104B1 (en) * 2015-11-26 2016-12-02 (주)퓨젠바이오농업회사법인 Composition for kidney protection comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
JP2020525405A (en) * 2017-06-30 2020-08-27 フジェンビオ カンパニー, リミテッドFugenbio Co., Ltd. Wound healing pharmaceutical composition containing Ceripolia laserata culture
KR101925890B1 (en) * 2018-08-02 2018-12-06 김병천 Novel strain of Ceriporia lacerata-K1, and composition comprising its culture for preventing or treating diabetes mellitus
KR101981571B1 (en) * 2018-10-12 2019-05-24 김병천 Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating hepatic injury
KR101969433B1 (en) * 2018-10-12 2019-04-17 김병천 Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating diabetes mellitus
CN111518825B (en) * 2020-04-30 2022-10-11 浙江工业大学 Method for preparing cordyceps militaris polysaccharide through polygene combined expression
KR102297056B1 (en) * 2020-08-20 2021-09-06 주식회사 마이셀랩 Culture broth of Porostereum sp.(KCTC18837P) and composition comprising the same for preventing or treating diabetes mellitus
KR102380296B1 (en) * 2021-06-15 2022-03-28 롱런 메디칼 푸드 피티이. 엘티디. Culture broth of Irpex lacteus mycelium and composition comprising the same for preventing or treating diabetes mellitus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101138464B1 (en) * 2004-07-06 2012-04-25 환인제약 주식회사 Inonotus obliqqus WI0628, its extract with antidiabetic activity and its extraction method
JP2008245629A (en) * 2007-03-30 2008-10-16 Kyushu Univ Microbial preparation for treatment of woody waste
JP5561637B2 (en) * 2010-02-16 2014-07-30 国立大学法人鳥取大学 Antibacterial / sterilization technology using mushroom volatile antibacterial substances
KR101031605B1 (en) * 2010-11-11 2011-04-27 김병천 Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same
CN102807956B (en) * 2012-07-12 2014-04-16 华东理工大学 Ceriporia lacerata strain and application thereof

Also Published As

Publication number Publication date
CN105142655B (en) 2020-11-17
DE112013006456T5 (en) 2015-10-01
CA2897955A1 (en) 2014-07-24
WO2014112666A1 (en) 2014-07-24
AU2013374516B2 (en) 2017-02-02
GB201514369D0 (en) 2015-09-30
JP2016506719A (en) 2016-03-07
AU2013374516A1 (en) 2015-08-27
CA2897955C (en) 2018-01-16
CN105142655A (en) 2015-12-09
KR20150103690A (en) 2015-09-11
GB2529557A (en) 2016-02-24

Similar Documents

Publication Publication Date Title
BR112015017069A2 (en) process for preparing extract from ceriporialacerata culture medium and pharmaceutical compositions prepared for the prevention or treatment of diabetic diseases and diabetic complications, which contain ceriporialacerata culture medium extract as active ingredient
BR112018075734A2 (en) compound, pharmaceutical composition, method of treating a patient with a disease or condition mediated at least in part by fxr, and use of a compound.
BR112017022776A2 (en) polysaccharide-streptococcal protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112019008458A2 (en) 1,2,4-triazolones 2,4,5-trisubstituted.
BR112018068986A2 (en) composition for reducing mir-3120 expression in an individual's cell or tissue, method for reducing mir-3120 expression in an individual's cell or tissue, and method for producing ips cells
BR112015007183A2 (en) compositions, use of a composition, method for combating fungi and seed
BR112017002221A2 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
EA201300550A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION
BR112017018022A2 (en) "antiviral compounds, pharmaceutical composition comprising said compounds and uses thereof
WO2019066577A3 (en) Composition for diagnosis and treatment of alcoholic liver disease, using change in short-chain fatty acid producing gut bacterial community
BR112017012327A8 (en) benzamides substituted by 1,3-thiazol-2-yl.
BR112013006396A2 (en) immunogenic compositions
MX370853B (en) Formulations containing amorphous dapagliflozin.
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections
BR112015022566A2 (en) compound and pharmaceutical composition
BR112012016376A2 (en) substituted pyrrolo-aminopyrimide compounds
BR112013027554A2 (en) "uses of compounds in the treatment of alzheimer's disease, huntington's disease, autism and other disorders"
BR112015008552A2 (en) crystalline material, pharmaceutical composition, and process for the preparation of a crystalline material
BR112015028278A2 (en) process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and erythrocytes thus obtained
BR112016021648A2 (en) new compounds
BR112015030385A8 (en) compound, compound for use and pharmaceutical composition
BR112015018504A2 (en) flap modulators
BR112013030391A2 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
BR112013029417A2 (en) protein matrix vaccine compositions including polycations
BR112017024727A2 (en) cocrystal, pharmaceutical composition, method of treatment of a disease in an individual and production process of a cocrystal

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)